Business Description
Cipla Ltd
ISIN : INE059A01026
Share Class Description:
BOM:500087: Shs DematerialisedCompare
Compare
Traded in other countries / regions
500087.IndiaCIPLA.Luxembourg IPO Date
1992-03-02Description
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 18.87 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.07 | |||||
| Interest Coverage | 92.36 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 13.34 | |||||
| Beneish M-Score | -2.28 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.2 | |||||
| 3-Year EBITDA Growth Rate | 14.7 | |||||
| 3-Year EPS without NRI Growth Rate | 19.8 | |||||
| 3-Year FCF Growth Rate | -1.8 | |||||
| 3-Year Book Growth Rate | 13.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 8.33 | |||||
| Future 3-5Y Total Revenue Growth Rate | 8.1 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.67 | |||||
| 9-Day RSI | 43.1 | |||||
| 14-Day RSI | 43.19 | |||||
| 6-1 Month Momentum % | 0.71 | |||||
| 12-1 Month Momentum % | 24.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.84 | |||||
| Quick Ratio | 2.82 | |||||
| Cash Ratio | 1.6 | |||||
| Days Inventory | 208.11 | |||||
| Days Sales Outstanding | 70.69 | |||||
| Days Payable | 100.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.87 | |||||
| Dividend Payout Ratio | 0.24 | |||||
| Forward Dividend Yield % | 0.87 | |||||
| 5-Year Yield-on-Cost % | 0.87 | |||||
| Shareholder Yield % | 1.19 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.63 | |||||
| Operating Margin % | 21.98 | |||||
| Net Margin % | 17.1 | |||||
| FCF Margin % | 10.64 | |||||
| ROE % | 16.8 | |||||
| ROA % | 13.6 | |||||
| ROIC % | 19.03 | |||||
| ROC (Joel Greenblatt) % | 48.52 | |||||
| ROCE % | 22.56 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 26.94 | |||||
| Forward PE Ratio | 26.2 | |||||
| PE Ratio without NRI | 27.05 | |||||
| Shiller PE Ratio | 44.83 | |||||
| Price-to-Owner-Earnings | 31.5 | |||||
| PEG Ratio | 2.06 | |||||
| PS Ratio | 4.59 | |||||
| PB Ratio | 4.24 | |||||
| Price-to-Tangible-Book | 5.18 | |||||
| Price-to-Free-Cash-Flow | 43.29 | |||||
| Price-to-Operating-Cash-Flow | 29.14 | |||||
| EV-to-EBIT | 18.11 | |||||
| EV-to-Forward-EBIT | 17.75 | |||||
| EV-to-EBITDA | 15.74 | |||||
| EV-to-Forward-EBITDA | 14.69 | |||||
| EV-to-Revenue | 4.28 | |||||
| EV-to-Forward-Revenue | 3.59 | |||||
| EV-to-FCF | 39.55 | |||||
| Price-to-Projected-FCF | 2.43 | |||||
| Price-to-DCF (Earnings Based) | 1.81 | |||||
| Price-to-DCF (FCF Based) | 1.98 | |||||
| Price-to-Median-PS-Value | 1.31 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.84 | |||||
| Price-to-Graham-Number | 2.5 | |||||
| Price-to-Net-Current-Asset-Value | 8.22 | |||||
| Price-to-Net-Cash | 49.88 | |||||
| Earnings Yield (Greenblatt) % | 5.53 | |||||
| FCF Yield % | 2.31 | |||||
| Forward Rate of Return (Yacktman) % | 15.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cipla Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 261,741.1 | ||
| EPS (TTM) (₹) | 55.38 | ||
| Beta | 0.58 | ||
| Volatility % | 17.53 | ||
| 14-Day RSI | 43.19 | ||
| 14-Day ATR (₹) | 35.573336 | ||
| 20-Day SMA (₹) | 1520.6875 | ||
| 12-1 Month Momentum % | 24.19 | ||
| 52-Week Range (₹) | 1191.75 - 1702 | ||
| Shares Outstanding (Mil) | 807.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cipla Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cipla Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cipla Ltd Frequently Asked Questions
What is Cipla Ltd(BOM:500087)'s stock price today?
The current price of BOM:500087 is ₹1491.55. The 52 week high of BOM:500087 is ₹1702.00 and 52 week low is ₹1191.75.
When is next earnings date of Cipla Ltd(BOM:500087)?
The next earnings date of Cipla Ltd(BOM:500087) is 2025-01-24 Est..
Does Cipla Ltd(BOM:500087) pay dividends? If so, how much?
The Dividend Yield %  of Cipla Ltd(BOM:500087) is 0.87% (As of Today), Highest Dividend Payout Ratio of Cipla Ltd(BOM:500087) was 0.32. The lowest was 0.1. And the median was 0.14. The  Forward Dividend Yield % of Cipla Ltd(BOM:500087) is 0.87%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers